ABIVAX Société Anonyme (EPA:ABVX)

Market Cap	7.86B
Revenue (ttm)	5.31M -42.9%
Net Income	-293.52M
EPS	-4.46
Shares Out	77.83M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	131,419
Average Volume	197,885
Open	100.40
Previous Close	101.00
Day's Range	96.10 - 100.40
52-Week Range	4.51 - 132.00
Beta	-0.25
RSI	41.90
Earnings Date	Mar 23, 2026

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 67
• Stock Exchange: Euronext Paris
• Ticker Symbol: ABVX

Financial Performance

In 2024, ABIVAX Société Anonyme's revenue was 10.79 million, an increase of 135.94% compared to the previous year's 4.57 million. Losses were -176.24 million, 19.3% more than in 2023.